Literature DB >> 12718907

Lipid-protamine-DNA-mediated antigen delivery to antigen-presenting cells results in enhanced anti-tumor immune responses.

John Dileo1, Rajkumar Banerjee, Mark Whitmore, Jayakar V Nayak, Louis D Falo, Leaf Huang.   

Abstract

Vaccination with antigenic peptides encoding tumor antigens has the potential to be an effective treatment for cancer. To induce tumor-specific cellular immune responses, a peptide antigen must be presented by antigen-presenting cells (APCs) to T-cells in the lymphatic tissues. Effective in vivo delivery of peptide antigens to APCs has been problematic. Here we use a model antigen from the HPV16 E7 protein to formulate LPD/E7 particles that upon iv administration are internalized by CD11c(+) and CD11b(+) cells in the marginal zone of the spleen. Either iv or sc vaccination with LPD/E7 particles induces E7-specific CTL responses stronger than those obtained using previously described liposome/peptide strategies and prevents the establishment of E7-expressing tumors. Furthermore, the administration of LPD/E7 particles to tumor-bearing mice caused complete tumor regression in 100% of the treated animals. Based on these studies, the entrapment of peptide antigens inside LPD particles may be an effective and generally applicable strategy for the enhancement of peptide vaccine potency.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12718907     DOI: 10.1016/s1525-0016(03)00064-9

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  10 in total

Review 1.  Lipid-based nanoparticles for nucleic acid delivery.

Authors:  Weijun Li; Francis C Szoka
Journal:  Pharm Res       Date:  2007-03       Impact factor: 4.200

Review 2.  Multifunctional nanoparticles for cancer immunotherapy.

Authors:  Tayebeh Saleh; Seyed Abbas Shojaosadati
Journal:  Hum Vaccin Immunother       Date:  2016-02-22       Impact factor: 3.452

Review 3.  Messenger RNA (mRNA) nanoparticle tumour vaccination.

Authors:  Kyle K L Phua; Smita K Nair; Kam W Leong
Journal:  Nanoscale       Date:  2014-07-21       Impact factor: 7.790

4.  Coating of mannan on LPD particles containing HPV E7 peptide significantly enhances immunity against HPV-positive tumor.

Authors:  Zhengrong Cui; Su-Ji Han; Leaf Huang
Journal:  Pharm Res       Date:  2004-06       Impact factor: 4.200

5.  Induction of cytotoxic T-lymphocytes and antitumor activity by a liposomal lipopeptide vaccine.

Authors:  Weihsu Chen; Leaf Huang
Journal:  Mol Pharm       Date:  2008-02-12       Impact factor: 4.939

Review 6.  Cancer immunotherapy and nanomedicine.

Authors:  Wei-Yun Sheng; Leaf Huang
Journal:  Pharm Res       Date:  2010-09-04       Impact factor: 4.580

7.  Design and characterization of novel recombinant listeriolysin O-protamine fusion proteins for enhanced gene delivery.

Authors:  Na Hyung Kim; Chester Provoda; Kyung-Dall Lee
Journal:  Mol Pharm       Date:  2015-01-22       Impact factor: 4.939

Review 8.  Nanotherapy for Cancer: Targeting and Multifunctionality in the Future of Cancer Therapies.

Authors:  Asiri Ediriwickrema; W Mark Saltzman
Journal:  ACS Biomater Sci Eng       Date:  2015-01-13

Review 9.  Synthetic Approaches for Nucleic Acid Delivery: Choosing the Right Carriers.

Authors:  Rong Ni; Ruilu Feng; Ying Chau
Journal:  Life (Basel)       Date:  2019-07-09

Review 10.  Therapeutic Vaccine Strategies against Human Papillomavirus.

Authors:  Hadeel Khallouf; Agnieszka K Grabowska; Angelika B Riemer
Journal:  Vaccines (Basel)       Date:  2014-06-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.